Clinical trial NCT06439888: Lymphocyte Support to SBRT in Patients With Oligo-metastatic Solid Cancer
Official title: Pan-lesions SBRT Combined With Lymphocyte Support Through ATRA-driven Blockade of MDSC in Patients With Oligo-metastatic Solid Cancer
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
PHASE2
Conditions: Oligometastatic Disease
Solid Tumor, Adult
Lead sponsor: Gustave Roussy, Cancer Campus, Grand Paris
Sponsor class: OTHER
First posted: 2024-06-03
Enrollment: 58
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The goal of this clinical trial is to assess safety of pan-metastases directed SBRT combined with ATRA and the lympho-protective efficacy of ATRA upon radiation-induced lymphopenia.

This is a French bicentric, open label, phase I/II clinical study that will comprise two parts. Part I will evaluate the safety of the combination based on a single-arm safety run design, while Part II will be randomized (ratio 1:1) and will study SBRT with or without ATRA.

Patients enrolled will be treated with:

* SBRT to all lesions more than 1.5cm, on week days (from Monday to Friday), over a maximum of 2 weeks,
* With or without (for part II patients randomized in the control arm) ATRA therapy: ATRA 150 mg/m\^2/day for 3 days every 3 weeks for a maximum of 4 cycles (about 3 months), starting on the first day of radiation therapy.

The expected rate of patients who will have lymphopenia of grade 2 or higher in the control arm at 6 weeks post-radiotherapy is 50%.

At a one-sided level of statistical significance of 0.07, the randomization of 52 patients (26 patients in each arm) will provide 85% power to detect a decrease in this rate to 15% in the SBRT+ATRA arm, using Fisher's exact test.

Detailed description: Ablative radiotherapy - also called stereotactic body radiation therapy (SBRT) - can achieve durable control of tumor lesions and appears as a highly promising strategy to extend overall survival of patients with oligo-metastatic diseases. Radiotherapy has recognized immunomodulatory effects: it triggers immunogenic cell death and reprogramming of the tumor immune microenvironment, which eventually results in a systemic antitumor response following focal radiation treatment. This is called the abscopal effect (distant out-of-the-field lesions that shrink after focal irradiation). Unfortunately, evidences show that this is directly counteracted by the toxic effects of radiotherapy on cytotoxic lymphocytes, which are highly radiosensitive.

Recent data support the fact that radiation-induced lymphopenia is mostly driven by the deregulation of the myeloid-lymphoid imbalance following radiation therapy, with aberrant myelopoiesis and high levels of tumor infiltration by myeloid-derived suppressive cells (MDSC). In preclinical models, pharmacological blockade of MDSC combined with radiation therapy successfully abrogated radiation-induced lymphopenia and significantly improved survival outcomes.

All trans retinoic acid (ATRA, also known as tretinoin) is a vitamin A derivative that has a market authorization for the treatment of acute promyelocytic leukemia as it efficiently induces differentiation of abnormal promyelocytes. Similarly, several clinical studies report that ATRA can differentiate MDSCs into mature myeloid cells, with a positive effect on the count of activated cluster of differentiation 8 (CD8+) lymphocytes.

This clinical trial will provide the clinical proof-of-concept that adding ATRA to pan-metastases SBRT is safe in humans, prevents severe and prolonged lymphopenia and therefore, may foster a radiation-induced systemic anticancer immune response sufficient to increase survival in patients with cancer at the oligo-metastatic stage.

Eligibility criteria: Inclusion Criteria:

* Adult male or female patients (older than 18 years of age at inclusion);
* Histologically or cytologically proven solid cancer at the oligo-metastatic stage amenable to pan-lesion SBRT, as defined by:

  1. 2 to 5 tumor lesions measurable as per RECIST V1.1 (including primary) with a largest diameter comprised between 1.5 and 5 cm,
  2. The disease can be either genuinely oligo-metastatic, oligo-progressive, or an induced oligo-metastatic disease,
  3. All tumor lesions that match criterion I2a must be eligible to SBRT in terms of location and radiotherapy constraints,
  4. SBRT to all lesions must be feasible over a two-week period,
  5. Whatever the primary tumor type;
* Patients must agree to comply with biopsy and blood sampling for research purpose;
* Minimal wash-out periods from last administration of treatments to the first day of SBRT must be:

  1. Systemic chemotherapy including cytotoxic, immunotherapy, targeted therapy, hormone therapy, any investigational agent during the last 4 weeks,
  2. Immunosuppressive medication during the last 4 weeks, with the exceptions of intranasal, topical, and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceeding 10 mg/day of prednisone, or an equivalent corticosteroid,
  3. Live attenuated vaccination during the last 4 weeks,
  4. Major surgery during the last 4 weeks;
* World Health Organization (WHO) 0 or 1 and Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1;
* Patients must have adequate organ function defined as follows:

  1. White blood cell count of equal to or higher than 1,500/mm\^3,
  2. Lymphocyte count of equal to or higher than 800/mm\^3,
  3. Platelet count of equal to or higher than 100,000/mm\^3,
  4. Hemoglobin higher than 9 g/dL,
  5. Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) equal to or less than 2.5 upper level norm (or if liver metastases are present must be equal to or less than 5x upper level norm)
  6. Serum creatinine clearance higher than 40 mL/min by the Cockcroft-Gault formula (Cockcroft and Gault 1976) or by 24-hour urine collection for determination of creatinine clearance;
* Female patients must either be of non-reproductive potential or must have a negative serum pregnancy test within 3 days prior to the initiation of the study drug. Fertile men with a female partner of childbearing potential must agree to use male condom plus spermicide and childbearing potential women must have agreed to use at least one highly effective contraceptive method during treatment on this trial and for up to 1 month after the last dose of ATRA; Pregnancy testing and contraception counseling should be repeated monthly throughout the period of ATRA treatment.
* Patient should understand, sign, and date the written voluntary informed consent form prior to any protocol-specific procedures performed. Patient should be able and willing to comply with study visits and procedures as per protocol;
* Patients must be affiliated to a social security system or beneficiary of the same

Exclusion Criteria:

* Evidence of disease rapidly progressing at the time of screening according to the two last best-fitted imaging modalities (CT-scans, MRI, positron emission tomography), at the discretion of the investigator and the multidisciplinary board (RCP);
* Any evidence of brain metastasis;
* Any situation where irradiation of the target site(s) would imply re-irradiation of a formerly irradiated tumor site;
* Bone metastasis located in a femoral bone if risk of pending fracture is high;
* Liver metastasis adjacent to the stomach or small bowel and liver metastasis that leads to a volume of uninvolved liver less than 700 cc;
* Patients with any concurrent severe condition (grade 3 or beyond according to CTCAE V5.0) and/or uncontrolled medical condition that could compromise participation in the study;
* Any psychiatric illness or social situations that would limit compliance with study requirements or compromise the ability of the subject to give written informed consent;
* Active secondary malignancy unless the malignancy is not expected to interfere with the evaluation of safety and is approved by the Sponsor. Examples of the latter include basal or squamous cell carcinoma of the skin, in-situ carcinoma of the cervix, and isolated elevation of prostate-specific antigen. Patients with a completely treated prior malignancy who are no longer treated (including maintenance therapy) and no evidence of disease for at least 2 years are eligible;
* Chronic treatment with systemic corticosteroids or another immunosuppressant including, but not limited to systemic corticosteroids at doses exceeding 10 mg/day of prednisone or equivalent, methotrexate, azathioprine, and tumor necrosis factor-α (TNF-α) blockers. Use of immunosuppressive medications for the management of investigational product-related Adverse Events or in subjects with contrast allergies is acceptable. The use of topical, inhaled and intranasal corticosteroids is permitted;
* Patients with tumor(s) that invade major vessels, as shown unequivocally by imaging studies;
* Patients with central lung metastasis (i.e within 2 cm from hilum) that are cavitary as shown unequivocally by imaging studies;
* Persisting significant toxicities related to prior treatments i.e. Grade 2 and higher adverse event according to CTCAE V5.0 criteria, except for alopecia and biological values defined in inclusion criteria I6;
* Known allergy or hypersensitivity to the study drug. The study drug is contraindicated in patients with soy or peanut allergy;
* Positive test for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS);
* Patients at risk of QT prolongation (including patients with hypokaliemia, baseline QT/corrected QT interval more than 470 ms (for women) and more than 450 ms (for men));
* Pregnant or breastfeeding women;
* Persons deprived of their freedom or under guardianship, or for whom it would be impossible to undergo the medical follow-up required by the trial, for geographic, social or psychological reasons.

Primary outcomes:
measure: Dose-limiting toxicities (DLT)
timeFrame: from the first intake to 3 weeks after the treatment initiation
measure: Lympho-protective efficacy
timeFrame: At 6 weeks after SBRT completion
Secondary outcomes:
measure: Control rates
timeFrame: from 6 weeks to 1 year after SBRT
measure: Objective response rate
timeFrame: from 6 weeks to 1 year after SBRT
measure: Duration of response
timeFrame: from 6 weeks to 1 year after SBRT
measure: Progression-free survival
timeFrame: from 6 weeks to 1 year after SBRT
Other outcomes:
Locations:
city: Lyon
country: France
facility: Centre Léon Bérard
city: Villejuif
country: France
facility: Gustave Roussy
Study officials:
affiliation: Gustave Roussy, Cancer Campus, Grand Paris
name: Eric DEUTSCH, PhD, MD
role: PRINCIPAL_INVESTIGATOR
References: